compound 25ap [PMID: 37796543]   Click here for help

GtoPdb Ligand ID: 12932

Compound class: Synthetic organic
Comment: This compund is a multitarget agent that is designed to inhibit the BRD4-LIFR-JAK1-STAT3 signalling pathway in tumour cells in which this pathway has been implicated in resistance to HDAC inhibitors [3]. The design of 25ap was based on fedratinib, which has dual JAK/BRD4 inhibitory actions [1-2]. Functionally, 25ap acts as a potent HDAC/JAK/BRD4 triple inhibitor that simultaneously elevates acetylation of histone and α-tubulin, reduces STAT3 phosphorylation and downregulates transcription of leukemia inhibitory factor receptor (LIFR), MCL1 apoptosis regulator (MCL-1), and c-Myc oncogene in breast cancer cells, which mediate antiproliferative, pro-apoptotic and anti-clonogenic effects in vitro. In vivo antitumour efficacy was demonstrated in a MDA-MB-231 breast cancer xenograft model.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 4
Rotatable bonds 10
Topological polar surface area 110.58
Molecular weight 448.52
XLogP 0.24
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC1=C(NC2=CC=C(C=C2)C(=O)NO)N=C(N=C1)NC3=CC=C(C=C3)OCCN4CCCC4
Isomeric SMILES ONC(C1=CC=C(NC2=NC(NC=3C=CC(=CC3)OCCN4CCCC4)=NC=C2C)C=C1)=O
InChI InChI=1S/C24H28N6O3/c1-17-16-25-24(28-22(17)26-19-6-4-18(5-7-19)23(31)29-32)27-20-8-10-21(11-9-20)33-15-14-30-12-2-3-13-30/h4-11,16,32H,2-3,12-15H2,1H3,(H,29,31)(H2,25,26,27,28)
InChI Key JUIHREVFVXLZPR-UHFFFAOYSA-N
References
1. Ciceri P, Müller S, O'Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, Lasater EA, Pallares G, Picaud S, Wells C et al.. (2014)
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
Nat Chem Biol, 10 (4): 305-12. [PMID:24584101]
2. Ember SW, Zhu JY, Olesen SH, Martin MP, Becker A, Berndt N, Georg GI, Schönbrunn E. (2014)
Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors.
ACS Chem Biol, 9 (5): 1160-71. [PMID:24568369]
3. Zhao C, Zhang Y, Zhang J, Li S, Liu M, Geng Y, Liu F, Chai Q, Meng H, Li M et al.. (2023)
Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer.
J Med Chem, 66 (20): 14150-14174. [PMID:37796543]